Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer

Lung

Volumn 184, Issue 5, 2006, Pages 279-285

  Pirker, R ^a   Ulsperger, E ^b   Messner, J ^c   Aigner, K ^d   Forstner, B ^d   Bacon, P ^f   Easton, V ^e   Skacel, T ^f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

^c GENERAL HOSPITAL   (Austria)

^d ELISABETHINEN HOSPITAL   (Austria)

^e AMGEN LTD   (United Kingdom)

^f AMGEN INC   (United States)

Author keywords

Dose density; Febrile neutropenia; Hematopoietic growth factor; Pegfilgrastim; Small cell lung cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG FATALITY; DRUG FEVER; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPOKALEMIA; INTESTINE PERFORATION; KIDNEY FAILURE; LARYNX CANCER; LEUKOPENIA; LUNG EDEMA; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PANCYTOPENIA; PERIPHERAL EDEMA; PETECHIA; PLEURA EFFUSION; PRIORITY JOURNAL; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33846405724     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-005-2594-8     Document Type: Article

References (33)

1. Ardizzoni A, Tjan-Heijnen VCG, Postmus PE, et al. (2002) Standard versus intensified chemotherapy with granylocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer - Lung Cancer Group Phase III Trial 08923. J Clin Oncol 20:3947-3955
2. Bentley MP, Norvath N, Lewis ID, et al. (2003) Single dose per cycle pegfilgrastim successfully supports full dose intensity CHOP-14 in patients over 60 years with non-Hodgldn's lymphoma (NHL) and successfully mobilizes peripheral blood progenitor cells (PBPC). Blood 102:abstract 2348
3. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332:901-906
4. Budman DR, Berry DA, Cirrincione CT, et al. (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205-1211
5. Citron ML, Berry DA, Cirrincione C, et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439
6. Crawford J, Ozer H, Stoller R, et al. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170
7. Dunlop DJ, Eatock MM, Paul J, et al. (1998) Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol) 10:107-114
8. Epelbaum R, Faraggi D, Ben-Arie Y, et al. (1990) Survival of diffuse large cell lymphoma: a muitivariate analysis including dose intensity variables. Cancer 66:1124-1129
9. Green MD, Koelbl H, Baselga J, et al. (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35
10. Grigg A, Solal-Celigny P, Hoskin P, et al. (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 44:1503-1508
11. Holmes FA, Jones SE, O'Shaughnessy J, et al. (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903-909
12. Ihde DC (1995) Small cell lung cancer. State-of-the-art therapy 1994. Chest 107:243S-248S
13. Ihde DC, Mulshine JL, Kramer BS, et al. (1994) Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022-2034
14. Johnson DH, Einhorn LH, Birch R, et al. (1987) A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731-1738
15. Johnston E, Crawford J, Blackwell S, et al. (2000) Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522-2528
16. Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963-977
17. Lepage E, Gisselbrecht C, Haioun C, et al. (1993) Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. Ann Oncol 4:651-656
18. Lyman GH, Morrison VA, Dale DC, et al. (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 44:2069-2076
19. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 22:4302-4311
20. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
21. Moore TD, Patel T, Segal ML, et al. (2003) A single pegfil-grastim dose per cycle supports dose-dense (q14d) CHOP-R in patients with non-Hodgkin's lymphoma. Blood 102:abstract 2365
22. National Cancer Institute (2003) Small Cell Lung Cancer Treatment, vol 2004. US National Institutes of Health, Washington, DC
23. Noda K, Nishiwaki Y, Kawahara M, et al. (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91
24. Pfreundschuh M, Truemper L, Kloess M, et al. (2004) 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641
25. Steward WP, von Pawel J, Gatzemeier U, et al. (1998) Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 16:642-650
26. Thatcher N, Anderson H, Bleehen NM, et al. (1995) The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Research Council Lung Cancer Working Party. Eur J Cancer 31A:152-156
27. Thatcher N, Clark PI, Smith DB, et al. (1995) Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 7:293-299
28. Thatcher N, Girling DJ, Hopwood P, et al. (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18:395-404
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
30. Trillet-Lenoir V, Green J, Manegold C, et al. (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324
31. Vose JM, Crump M, Lazarus H, et al. (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21:514-519
32. Woll PJ, Hodgetts J, Lomax L et al. (1995) Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13:652-659
33. Younes A, Fayad L, Romaguera J, et al. (2003) Single administration of a fixed dose pegfilgrastim (Neulasta) in inducing neutrophil count recovery after 170 consecutive doses of ABVD chemotherapy in patients with Hodgkin lymphoma: safety of pegfilgrastim with q14-day chemotherapy regimens. Blood 102:637a